ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 24 of 46 for:    osteogenesis imperfecta

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 (ASTEROID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03118570
Recruitment Status : Recruiting
First Posted : April 18, 2017
Last Update Posted : August 17, 2018
Sponsor:
Collaborator:
ICON Clinical Research
Information provided by (Responsible Party):
Mereo BioPharma

Brief Summary:
The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.

Condition or disease Intervention/treatment Phase
Osteogenesis Imperfecta, Type I Osteogenesis Imperfecta Type III Osteogenesis Imperfecta Type IV Drug: BPS804 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-blind, Dose-finding Study, incorporating an open-label substudy
Masking: Double (Participant, Investigator)
Masking Description: Sponsor will be masked until the primary analysis of the study except for open-label substudy treatment arm. The study site pharmacist will be unmasked to treatment allocation throughout. Study treatment will be monitored by a separate unmasked monitoring team.
Primary Purpose: Treatment
Official Title: Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Actual Study Start Date : September 11, 2017
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : October 31, 2020


Arm Intervention/treatment
Experimental: BPS804 Dose 1
BPS804 IV Infusion
Drug: BPS804
Intravenous infusion
Other Name: setrusumab

Experimental: BPS804 Dose 2
BPS804 IV Infusion
Drug: BPS804
Intravenous infusion
Other Name: setrusumab

Experimental: BPS804 Dose 3
BPS804 IV Infusion
Drug: BPS804
Intravenous infusion
Other Name: setrusumab

Experimental: BPS804 Dose 4
BPS804 IV Infusion
Drug: BPS804
Intravenous infusion
Other Name: setrusumab




Primary Outcome Measures :
  1. Change in Trabecular Volumetric Bone Mineral Density (mgHA/cm3) [ Time Frame: 12 months ]
    High Resolution Peripheral Quantitative Computated Tomography

  2. Change in bone strength on Finite Element Analysis (N) [ Time Frame: 12 months ]
    High Resolution Peripheral Quantitative Computated Tomography


Secondary Outcome Measures :
  1. Change in Trabecular Volumetric Bone Mineral Density (mgHA/cm3) [ Time Frame: 12 months ]
    High Resolution Peripheral Quantitative Computative Tomography

  2. Change in bone strength on Finite Element Analysis (N) [ Time Frame: 12 months ]
    High Resolution Peripheral Quantitative Computative Tomography

  3. Change in Quality of Life Patient Reported Outcome Scores (total & sub-domains) [ Time Frame: 6 and 12 months ]
    OI-QOL-A

  4. Change in Quality of Life Patient Reported Outcome Scores (total & sub-domains) [ Time Frame: 6 and 12 months ]
    SF-12

  5. Change in Quality of Life Patient Reported Outcome Scores (total & sub-domains) [ Time Frame: 6 and 12 months ]
    EQ5D

  6. Changes in lumbar bone mineral density (t-score) [ Time Frame: 6 and 12 months ]
    Dual-energy x-ray absorptiometry

  7. Changes in whole body bone mineral density (t-score) [ Time Frame: 6 and 12 months ]
    Dual-energy x-ray absorptiometry

  8. Changes in proximal femur bone mineral density (t-score) [ Time Frame: 6 and 12 months ]
    Dual-energy x-ray absorptiometry


Other Outcome Measures:
  1. Serum concentrations of BPS804, anti-BPS804 antibodies and BPS804 neutralising antibodies [ Time Frame: 12 months ]
    Serum concentrations of BPS804, anti-BPS804 antibodies and BPS804 neutralising antibodies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a clinical diagnosis of OI Type I, III or IV with a confirmed defect in the COL1A1/COL1A2 genes, as confirmed by genetic testing
  • One or more fractures in the past 5 years
  • Capable of giving signed consent

Exclusion Criteria:

  • History of skeletal malignancies or other bone diseases (other than OI)
  • History of neural foraminal stenosis (except if due to scoliosis)
  • History of myocardial infarction, angina pectoris, ischaemic stroke or transient ischaemic attack
  • History of endocrine or thyroid/parathyroid conditions that could affect bone metabolism
  • Treatment with bisphosphonates within 3 months of randomisation
  • Treatment with teraparatide, denosomab or other anabolic/antiresorbative medications within 6 months of randomisation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118570


Contacts
Contact: Ian Hodgson, PhD +44 3330237300 enquiries@mereobiopharma.com
Contact: Anthony Hall, MB BS BSc +44 3330237300 enquiries@mereobiopharma.com

  Hide Study Locations
Locations
United States, Alabama
Mereo Investigator Site Recruiting
Birmingham, Alabama, United States, 35294
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, California
Mereo Investigator Site Suspended
San Francisco, California, United States, 94143
United States, Florida
Mereo Investigator Site Recruiting
Jacksonville, Florida, United States, 32207
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, Maryland
Mereo Investigator Site Recruiting
Baltimore, Maryland, United States, 21287
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, Massachusetts
Mereo Investigator Site Not yet recruiting
Boston, Massachusetts, United States, 012115
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, Minnesota
Mereo Investigator Site Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, Missouri
Mereo Investigator Site Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, New Mexico
Mereo Investigator Site Recruiting
Albuquerque, New Mexico, United States, 87106
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, Ohio
Mereo Investigator Site Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, Oregon
Mereo Investigator Site Recruiting
Portland, Oregon, United States, 97239
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, Pennsylvania
Mereo Investigator Site Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Mereo Investigator Site Recruiting
Pittsburgh, Pennsylvania, United States, 15225
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, Tennessee
Mereo Investigator Site Recruiting
Nashville, Tennessee, United States, 37232
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
United States, Texas
Mereo Investigator Site Recruiting
Houston, Texas, United States, 77030
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Canada, Ontario
Mereo Investigator Site Recruiting
Toronto, Ontario, Canada
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Canada, Quebec
Mereo Investigator Site Recruiting
Montreal, Quebec, Canada
Contact: Ian Hodgson       enquiries@mereobiopharma.com   
Mereo Investigator Site Recruiting
Quebec City, Quebec, Canada
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Denmark
Mereo Investigator Site Recruiting
Aarhus, Denmark
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Mereo Investigator Site Recruiting
Odense, Denmark
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
France
Mereo Investigator Site Recruiting
Paris, Paris Cedex 14, France
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Mereo Investigator Site Recruiting
Lyon, France
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Mereo Investigator Site Recruiting
Paris, France
Contact: Ian Hodgson       enquiries@mereobiopharma.com   
United Kingdom
Mereo Investigator Site Recruiting
Cambridge, Cambridgeshire, United Kingdom
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Mereo Investigator Site Recruiting
Newcastle upon Tyne, Newcastle, United Kingdom
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Mereo Investigator Site Recruiting
Oxford, Oxfordshire, United Kingdom
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Mereo Investigator Site Recruiting
Bristol, United Kingdom
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Mereo Investigator Site Recruiting
London, United Kingdom
Contact: Ian Hodgson, PhD       enquiries@mereobiopharma.com   
Sponsors and Collaborators
Mereo BioPharma
ICON Clinical Research
Investigators
Study Chair: Jay Shapiro, Prof. Johns Hopkins University
Principal Investigator: Francis Glorieux, Prof. Shriner's Hospital for Children, Montreal
Principal Investigator: Kassim Javaid, Assoc. Prof. Nuffield Orthopaedic Centre, University of Oxford Hospitals Foundation Trust

Additional Information:
Responsible Party: Mereo BioPharma
ClinicalTrials.gov Identifier: NCT03118570     History of Changes
Other Study ID Numbers: MBPS205
2016-005096-27 ( EudraCT Number )
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: August 17, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Mereo BioPharma:
Osteogenesis Imperfecta
Brittle Bone Disease

Additional relevant MeSH terms:
Osteogenesis Imperfecta
Osteochondrodysplasias
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Genetic Diseases, Inborn
Collagen Diseases
Connective Tissue Diseases